Damora Therapeutics logo
Damora Therapeutics
GLTO | NASDAQ
Chart Builder DCF Calculator
$21.58
-$0.75 (-3.36%)
At close: Jun 4, 2026, 12:02 PM ET

Damora Therapeutics Company Profile

Company profile explained

Company Profile

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Key Executives

Name Position
Hans T. Schambye Co-Founder, President, Chief Executive Officer & Director
Lori C. Firmani Chief Financial Officer
Becker Hewes Chief Medical Officer
Garrett Winslow Senior Vice President, General Counsel & Corporate Secretary
Hakon Leffler Co-Founder
Matthew Kronmiller EVice President of Strategy & Chief Business Officer
Sherwin Sattarzadeh Interim Principal Executive Officer & COO
Tariq Sethi FRCP Co-Founder
Ulf J. Nilsson Co-Founder

Latest SEC Filings

Date Type Title
Sep 28, 2026 4 Filing
Aug 13, 2026 4 Filing
Aug 13, 2026 3 Filing
Aug 12, 2026 EFFECT Filing
Aug 10, 2026 S-8 POS Filing
Aug 10, 2026 S-8 POS Filing
Aug 10, 2026 POSASR Filing
Aug 10, 2026 S-8 POS Filing
Aug 10, 2026 S-8 POS Filing
Aug 10, 2026 S-8 POS Filing
View All SEC Filings ➞
Damora Therapeutics
Damora Therapeutics logo
Country United States
IPO Date Oct 28, 2020
Industry Medical - Pharmaceuticals
Sector Healthcare
Employees 7
CEO Jennifer A. Jarrett

Contact Details

Building 23 Boston, Massachusetts 02453 United States

Stock Details

Ticker Symbol GLTO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001800315
CUSIP Number 36322Q206
ISIN Number US36322Q2066
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.